Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KDM5A | P29375 | 7/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949690 | 0.91 | EPHX2 (0.50) | ALDH1A1EPHX2SIGMAR1KDM5AKDM4C | |
| SCHEMBL6956140 | 0.91 | EPHX2 (0.50) | ALDH1A1EPHX2SIGMAR1KDM5AKDM4C | |
| SCHEMBL4998095 | 0.86 | — | — | |
| SCHEMBL22160249 | 0.83 | TRPA1 (0.40) | CA12CA1CA9ALDH1A1 | |
| SCHEMBL5207863 | 0.82 | ALDH1A1 (0.43) | CA12CA1CA9ALDH1A1EPHX2 | |
| SCHEMBL4146764 | 0.81 | ALDH1A1 (0.46) | CA12CA1CA9ALDH1A1EPHX2 | |
| SCHEMBL948161 | 0.81 | ALDH1A1 (0.46) | CA12CA1CA9ALDH1A1EPHX2 | |
| SCHEMBL7131814 | 0.81 | EPHX2 (0.49) | CA12CA1CA9ALDH1A1EPHX2 | |
| SCHEMBL20673423 | 0.79 | ALDH1A1 (0.62) | CA12CA1CA9ALDH1A1EPHX2 | |
| SCHEMBL11161106 | 0.79 | EPHX2 (0.50) | CA12CA1CA9ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-7145015-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-12-05 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-0885215-B1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1609790-A2 | Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | Abbott Laboratories (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | disclosed |
| US-6790971-B1 | AMIDE OR CARBAMATE FUNCTION AT 11 BETA-POSITION; CLAIMED 3-ONE-DIENE INTERMEDIATE HAS HYDROXYMETHYLALKYL GROUP ON 11 POSITION; ANTIPROGESTOMIMETIC; HORMONE-DEPENDENT TUMORS; ANIMAL HUSBANDRY | AVENTIS PHARMA S.A. (FR) | 2004-09-14 | — | — | US | disclosed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | disclosed |
| EP-0776324-A1 | ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5622971-A | PIPERIDINE DERIVATIVES; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1997003046-A1 | TRIPHENYL ETHYLENES WITH ANTI-OESTROGENIC PROPERTIES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
| US-5290771-A | 19-nor-steroids | ROUSSEL UCLAF (FR) | 1994-03-01 | — | — | US | disclosed |
| EP-0384842-B1 | 19-Nor steroids substituted at position 11-beta by a hydrocarbon chain containing an amide or carbamate group, their preparation, intermediates, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1993-12-29 | — | — | EP | disclosed |
| US-5149696-A | Antiestrogens | ROUSSEL UCLAF (FR) | 1992-09-22 | — | — | US | disclosed |
| EP-0471612-A2 | New steroids having an amide substituted group in the 11-beta position, their preparation, their use as medicines and pharmaceutical composition thereof | ROUSSEL UCLAF (FR) | 1992-02-19 | — | — | EP | disclosed |
| CN-1046166-A | Contain the preparation method that the new 19-of 11 β-carbonated chain removes the first steroidal compounds | ROUSSEL UCLAF (FR) | 1990-10-17 | — | — | CN | disclosed |
| EP-0384842-A1 | 19-Nor steroids substituted at position 11-beta by a hydrocarbon chain containing an amide or carbamate group, their preparation, intermediates, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESR2, ESRRA | CA12 4451/4885CA1 4402/4885CA9 3541/4885 |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESRRA, SULT2A1 | CA12 4615/4885CA1 4371/4885CA9 4179/4885 |
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | CA12 3062/4885CA1 2416/4885CA9 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.